Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)

Sponsor
Texas Tech University Health Sciences Center, El Paso (Other)
Overall Status
Recruiting
CT.gov ID
NCT03125811
Collaborator
(none)
300
2
2
64.5
150
2.3

Study Details

Study Description

Brief Summary

This study will compare two different ways to relieve nausea and vomiting in the Emergency Department. The usual treatment for nausea/vomiting is a drug called Zofran, but new studies have suggested that smelling alcohol pads can also help to relieve nausea and vomiting.

Condition or Disease Intervention/Treatment Phase
  • Other: Inhaled Isopropyl Alcohol (IPA)
  • Drug: Oral Dissolvable Tablet Zofran (ondansetron)
Early Phase 1

Detailed Description

Emergency physicians commonly use medications to alleviate nausea and vomiting. The medication Ondansetron is used in the emergency department and after surgery for this purpose. Inhaled isopropyl alcohol has been successfully used to decrease nausea and vomiting after surgery. No trial has compared inhaled isopropyl alcohol to Ondansetron in a clinical trial.

The author proposes to prospectively investigate extension of the established antiemetic efficacy of inhaled isopropyl alcohol for undifferentiated nausea in Emergency Department patients to the 30-minute post-intervention point that has been reported to be the frequent juncture of symptom relief. By introducing prolonged intervention, and re-dosing of established benefit, into this research, the author aims to reproduce the sustained antiemetic efficacy of inhaled isopropyl alcohol for undifferentiated nausea as demonstrated for post-operative nausea and vomiting.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)
Actual Study Start Date :
Jul 17, 2017
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Inhaled Isopropyl Alcohol (IPA)

Inhaled Isopropyl Alcohol (alcohol prep pad)

Other: Inhaled Isopropyl Alcohol (IPA)
Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
Other Names:
  • IPA
  • alcohol prep pad
  • Other: Oral Dissolvable Tablet Zofran (OZ)

    4 mg Oral Dissolvable Tablet Zofran (ondansetron)

    Drug: Oral Dissolvable Tablet Zofran (ondansetron)
    Single dose 4 mg tablet at 0 minutes.
    Other Names:
  • OZ
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Nausea Severity [60 minutes]

      Patient's nausea severity will be assessed at three time points by the study personnel using a verbal nausea rating scale over the course 60 minutes. Severity is scored 0-10 (0 = no nausea; 10 = severe nausea). Time points are at 0 minutes, 30 minutes, and 60 minutes.

    Secondary Outcome Measures

    1. Emesis Event [60 minutes]

      Total number of emesis will be recorded for the 60 minute participation.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged 18-65 years presenting to the emergency department complaining of current nausea with or without episodes of emesis beginning within the previous 24hrs
    Exclusion Criteria:
    • Patients with known allergy to isopropyl alcohol

    • Patients outside of the defined age range

    • Patients with an inability to inhale through the nares (including recent upper respiratory infection)

    • Patients greater than 20 weeks estimated gestation

    • Patients with past medical history of gastroparesis, or hemoptysis

    • Patients who have taken an antiemetic medication in the past 48 hours

    • Patients demonstrating hemodynamic instability with systolic blood pressure <90 or tachycardia >120 bpm

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Texas Tech University Health Sciences Center El Paso El Paso Texas United States 79905
    2 University Medical Center El Paso Texas United States 79905

    Sponsors and Collaborators

    • Texas Tech University Health Sciences Center, El Paso

    Investigators

    • Principal Investigator: Scott Crawford, MD, Texas Tech Universtiy Health Sciences Center El Paso

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Scott Crawford, Associate Professor, Texas Tech University Health Sciences Center, El Paso
    ClinicalTrials.gov Identifier:
    NCT03125811
    Other Study ID Numbers:
    • E17005
    First Posted:
    Apr 24, 2017
    Last Update Posted:
    Apr 13, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Scott Crawford, Associate Professor, Texas Tech University Health Sciences Center, El Paso
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 13, 2022